CAJ | 학술논문

目的探讨伊立替康在晚期胃癌治疗中的效果及不良反应情况。方法选取我院2012年1月到2012年12月期间收治的晚期胃癌患者中的18例为研究对象，所有患者均采用伊立替康进行化疗，治疗过程中及治疗后，观察疗效和不良反应情况。结果经治疗，18例患者化疗有效率为50.0%，效果较为明显，但不良反应发生率稍高。结论伊立替康作为化疗药物应用于晚期胃癌化疗，效果良好，在减轻患者痛苦，提高患者治疗信心上临床表现较为卓著，虽然临床所致不良反应发生率高，但其仍可广泛应用于临床，作为晚期胃癌化疗药物。
목적탐토이립체강재만기위암치료중적효과급불량반응정황。방법선취아원2012년1월도2012년12월기간수치적만기위암환자중적18례위연구대상，소유환자균채용이립체강진행화료，치료과정중급치료후，관찰료효화불량반응정황。결과경치료，18례환자화료유효솔위50.0%，효과교위명현，단불량반응발생솔초고。결론이립체강작위화료약물응용우만기위암화료，효과량호，재감경환자통고，제고환자치료신심상림상표현교위탁저，수연림상소치불량반응발생솔고，단기잉가엄범응용우림상，작위만기위암화료약물。
Objective irinotecan in patients with advanced gastric cancer treatment effects and adverse reactions. Methods From January 2012 to December 2012 period were treated with advanced gastric cancer patients with 18 cases for the study, all patients were treated with irinotecan chemotherapy, treatment during and after treatment were observed efficacy and adverse reactions . Results After treatment, 18 patients with chemotherapy response rate was 50.0%, the effect is more obvious, but a slightly higher incidence of adverse reactions. Conclusion as irinotecan chemotherapy in advanced gastric cancer chemotherapy drug used to good effect in reducing the suffering of patients, improve patient confidence in the clinical manifestations of the more remarkable, although the incidence of clinical adverse reactions caused by, but still widely used in clinical, As advanced gastric cancer chemotherapy drugs.